Wuhan Yuancheng Gongchuang Technology Co., Ltd.

Cetilistat, CAS: 282526-98-1, Androlon manufacturer / supplier in China, offering Pharma Grade Weight Loss Medicine Cetilistat CAS 282526-98-1, Bp/USP Lyrica (Pregabalin) Anti-Epileptic Drug Raw Powder, Highest Quality 99% Purity Dl-10-Camphorsulfonic Acid CAS: 5872-08-2 and so on.

Supplier Homepage Product List Steroid Hormone Powders Weight Loss Drugs Pharma Grade Weight Loss Medicine Cetilistat CAS 282526-98-1

Pharma Grade Weight Loss Medicine Cetilistat CAS 282526-98-1

FOB Price:US $353 / kg
Min. Order (kg) FOB Price
1+ US $353 / kg
Get Latest Price
Min. Order: 1 kg
Production Capacity: 100kg/Month
Transport Package: 1kg/Bag, as Customers Request
Payment Terms: T/T, Western Union, Money Gram, Bitcoin

Basic Info.

Model NO.:CAS: 282526-98-1
Powder:Yes
Customized:Non-Customized
Certification:ISO 9001
Suitable for:Adult
State:Solid
Purity:>99%
M. F.:C22h32o3
M. W.:344.49
Export Markets:Global
Assay:99%
Packing:Stealth Pack
Terms of Payment:T/T, Western Union, Money Gram, Bitcoin
Shipping Method:EMS, DHL, TNT, FedEx, UPS
Delivery Time:Within 1-3 Days After Payment
Trademark:WHYCG testosterone propionate
Specification:USP
Origin:China

Product Description

Quick detail:

Product Name: Cetilistat
Synonyms: cetilistat;Cetilistat(Alt-962);Cetilstat;2-(Hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one;2-(Hexadecycloxy)-6-methyl-4H-3,1-benzoxazin-4-one;4H-3,1-Benzoxazin-4-one,2-(hexadecyloxy)-6-Methyl-;Xinli orlistat
CAS: 282526-98-1
MF: C25H39NO3
MW: 401.58
EINECS: 
Product Categories: Aromatics;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;API;Cetilistat
Mol File: 282526-98-1.mol

Cetilistat Chemical Properties
density: 1.02
CAS DataBase Reference: 282526-98-1(CAS DataBase Reference)

Cetilistat Usage And Synthesis
Chemical Properties: Off-white Cryst
Usage: A novel pancreatic lipase inhibitor for the treatment of obesity in both diabetic and non-diabetic patients.

 
Design:
Phase II, multicentre, randomized, placebo-controlled, parallel group study. Enrolled patients (N=442) were advised a hypocaloric diet (deficient by 500 kcal per day, 30% of calories from fat) for a 2-week run-in period. Patients who satisfied the entry criteria (N=371) continued on the hypocaloric diet and were randomized to either placebo or one of three different doses of cetilistat (60 mg three times daily t.i.d., 120 mg t.i.d. and 240 mg t.i.d.) for 12 weeks, followed by a 4-week post-treatment follow-up. Safety, tolerability and body weight were assessed, together with other parameters associated with obesity.
Outcome measures:
The primary outcome measure was absolute change in body weight from baseline. Secondary outcomes included the proportion of patients achieving pre-defined weight loss targets, changes from baseline in waist circumference and in blood lipids. GI tolerability criteria were specifically assessed, as was safety.
Results:
Treatment with cetilistat reduced mean body weight to similar extents at all doses, which were statistically significant compared with placebo (60 mg t.i.d. 3.3 kg, P<0.03; 120 mg t.i.d. 3.5 kg, P=0.02; 240 mg t.i.d. 4.1 kg, P<0.001). Total serum and low-density lipoprotein cholesterol levels were likewise significantly reduced by 3-11% at all doses of cetilistat. Cetilistat was well tolerated. The frequency of withdrawal owing to treatment-emergent adverse events was similar between cetilistat-treated groups (5.3-7.6%) and placebo (7.6%). Adverse events were generally mild to moderate in intensity, occurred on only one occasion and were mostly GI in nature. The incidence of GI adverse events was increased in the cetilistat-treated groups compared to placebo. However, those GI adverse events, such as flatus with discharge and oily spotting, only occurred in 1.8-2.8% of subjects in the cetilistat-treated groups.
Conclusions:
Cetilistat produced a clinically and statistically significant weight loss in obese patients in this short-term 12-week study. This was accompanied by significant improvements in other obesity-related parameters. Cetilistat treatment was well tolerated. The risk-benefit demonstrated in this study in terms of weight loss vs intolerable GI adverse effects shows that cetilistat merits further evaluation for the pharmacotherapy of obesity and related disorders.


OUR ADVANTAGE:

1, High quality with competitive price:
1)Standard:Enterprise Standard
2)All Purity≥99%
3)We are manufacturer and can provide high quality products with factory price.

2, Fast and safe delivery
1)Parcel can be sent out in 24 hours after payment.Tracking number available
2)Secure and discreet shipment.Various transportation methods for your choice.
3)Customs pass rate ≥99%
4) We have our own agent/remailer/distributor who can help us ship our products very fast and safe, and we have stock in there for transferring.

3, We have clients throughout the world.
1)Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet their desire.
2)Market feedback and goods feedback will be appreciated, meeting customers's requirement is our responsibility.
3) High quality, competitive price, fast delivery, first-class service gain the trust and praise from the customers.

 
Send your message to this supplier
Avatar
Mr. Ken
Sales Manager
*From
To Mr. Ken
*Message
Enter between 20 to 4,000 characters.
This is not what you are looking for? Post a Sourcing Request Now
Find Similar Products By Category:

Wuhan Yuancheng Gongchuang Technology Co., Ltd.

- Hubei, China
- Manufacturer/Factory, Trading Company

Gold Member Since 2012
Audited Supplier
  • Sample Available